• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房选择性K1.5和Na1.5通道中氟卡尼结合的常见结构模式:一种计算方法

Common Structural Pattern for Flecainide Binding in Atrial-Selective K1.5 and Na1.5 Channels: A Computational Approach.

作者信息

Mazola Yuliet, Márquez Montesinos José C E, Ramírez David, Zúñiga Leandro, Decher Niels, Ravens Ursula, Yarov-Yarovoy Vladimir, González Wendy

机构信息

Center for Bioinformatics, Simulation and Modeling (CBSM), Universidad de Talca, Talca 3460000, Chile.

Departamento de Farmacología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4030000, Chile.

出版信息

Pharmaceutics. 2022 Jun 27;14(7):1356. doi: 10.3390/pharmaceutics14071356.

DOI:10.3390/pharmaceutics14071356
PMID:35890252
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9318806/
Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its treatment includes antiarrhythmic drugs (AADs) to modulate the function of cardiac ion channels. However, AADs have been limited by proarrhythmic effects, non-cardiovascular toxicities as well as often modest antiarrhythmic efficacy. Theoretical models showed that a combined blockade of Na1.5 (and its current, ) and K1.5 (and its current, ) ion channels yield a synergistic anti-arrhythmic effect without alterations in ventricles. We focused on K1.5 and Na1.5 to search for structural similarities in their binding site (BS) for flecainide (a common blocker and widely prescribed AAD) as a first step for prospective rational multi-target directed ligand (MTDL) design strategies. We present a computational workflow for a flecainide BS comparison in a flecainide-K1.5 docking model and a solved structure of the flecainide-Na1.5 complex. The workflow includes docking, molecular dynamics, BS characterization and pattern matching. We identified a common structural pattern in flecainide BS for these channels. The latter belongs to the central cavity and consists of a hydrophobic patch and a polar region, involving residues from the S6 helix and P-loop. Since the rational MTDL design for AF is still incipient, our findings could advance multi-target atrial-selective strategies for AF treatment.

摘要

心房颤动(AF)是最常见的心律失常。其治疗方法包括使用抗心律失常药物(AADs)来调节心脏离子通道的功能。然而,AADs受到促心律失常作用、非心血管毒性以及通常较为有限的抗心律失常疗效的限制。理论模型表明,联合阻断Na1.5(及其电流, )和K1.5(及其电流, )离子通道可产生协同抗心律失常作用,且不会影响心室。我们聚焦于K1.5和Na1.5,以寻找它们与氟卡尼(一种常用的阻滞剂且是广泛处方的AAD)结合位点(BS)的结构相似性,作为前瞻性合理多靶点导向配体(MTDL)设计策略的第一步。我们展示了一种计算工作流程,用于在氟卡尼-K1.5对接模型和已解析的氟卡尼-Na1.5复合物结构中比较氟卡尼的BS。该工作流程包括对接、分子动力学、BS表征和模式匹配。我们在这些通道的氟卡尼BS中识别出一种共同的结构模式。后者属于中央腔,由一个疏水斑块和一个极性区域组成,涉及S6螺旋和P环的残基。由于针对AF的合理MTDL设计仍处于起步阶段,我们的发现可能会推动针对AF治疗的多靶点心房选择性策略的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/5b2edd2683db/pharmaceutics-14-01356-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/a09e9c03c3a7/pharmaceutics-14-01356-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/fc0d9ebcc716/pharmaceutics-14-01356-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/99767730c896/pharmaceutics-14-01356-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/4694b509b146/pharmaceutics-14-01356-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/09805ac1efb1/pharmaceutics-14-01356-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/d56a07a3828f/pharmaceutics-14-01356-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/1f21dd56ed5d/pharmaceutics-14-01356-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/5b2edd2683db/pharmaceutics-14-01356-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/a09e9c03c3a7/pharmaceutics-14-01356-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/fc0d9ebcc716/pharmaceutics-14-01356-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/99767730c896/pharmaceutics-14-01356-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/4694b509b146/pharmaceutics-14-01356-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/09805ac1efb1/pharmaceutics-14-01356-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/d56a07a3828f/pharmaceutics-14-01356-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/1f21dd56ed5d/pharmaceutics-14-01356-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08cd/9318806/5b2edd2683db/pharmaceutics-14-01356-g007.jpg

相似文献

1
Common Structural Pattern for Flecainide Binding in Atrial-Selective K1.5 and Na1.5 Channels: A Computational Approach.心房选择性K1.5和Na1.5通道中氟卡尼结合的常见结构模式:一种计算方法
Pharmaceutics. 2022 Jun 27;14(7):1356. doi: 10.3390/pharmaceutics14071356.
2
Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.钠通道阻滞剂与金合欢素联合使用对人心房的协同抗心律失常作用
Front Physiol. 2017 Nov 23;8:946. doi: 10.3389/fphys.2017.00946. eCollection 2017.
3
Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.心房静息膜电位使普罗帕酮、氟卡尼和决奈达隆对钠电流敏感。
Heart Rhythm. 2021 Jul;18(7):1212-1220. doi: 10.1016/j.hrthm.2021.03.016. Epub 2021 Mar 16.
4
Synergistic antiarrhythmic effect of combining inhibition of Ca²⁺-activated K⁺ (SK) channels and voltage-gated Na⁺ channels in an isolated heart model of atrial fibrillation.在心房颤动离体心脏模型中,联合抑制钙激活钾(SK)通道和电压门控钠通道的协同抗心律失常作用。
Heart Rhythm. 2015 Feb;12(2):409-18. doi: 10.1016/j.hrthm.2014.12.010. Epub 2014 Dec 10.
5
Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes.氟卡尼、奎尼丁和4-氨基吡啶对人心房肌细胞瞬时外向电流和超快速延迟整流电流的影响。
J Pharmacol Exp Ther. 1995 Jan;272(1):184-96.
6
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.肥胖介导的心房颤动与钠通道阻滞剂抗心律失常药物治疗之间的关联。
JAMA Cardiol. 2020 Jan 1;5(1):57-64. doi: 10.1001/jamacardio.2019.4513.
7
Revealing kinetics and state-dependent binding properties of I-targeting drugs that maximize atrial fibrillation selectivity.揭示靶向 I 通道药物的动力学和状态依赖性结合特性,以最大限度地提高心房颤动选择性。
Chaos. 2017 Sep;27(9):093918. doi: 10.1063/1.5000226.
8
Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.氟卡尼对小鼠RyR2-P2328S心脏的钠电流和房性心律失常产生矛盾的影响。
Acta Physiol (Oxf). 2015 Jul;214(3):361-75. doi: 10.1111/apha.12505. Epub 2015 Apr 23.
9
Use of Flecainide for the Treatment of Atrial Fibrillation.氟卡尼在心房颤动治疗中的应用。
Am J Cardiol. 2020 Apr 1;125(7):1123-1133. doi: 10.1016/j.amjcard.2019.12.041. Epub 2020 Jan 9.
10
Proarrhythmic Effects Of Antiarrhythmic Drugs: Case Study Of Flecainide Induced Ventricular Arrhythmias During Treatment Of Atrial Fibrillation.抗心律失常药物的促心律失常作用:氟卡尼在治疗心房颤动期间诱发室性心律失常的病例研究
J Atr Fibrillation. 2015 Dec 31;8(4):1091. doi: 10.4022/jafib.1091. eCollection 2015 Dec.

引用本文的文献

1
Rational design, synthesis, and evaluation of novel polypharmacological compounds targeting Na1.5, K1.5, and KP channels for atrial fibrillation.针对心房颤动,合理设计、合成及评估靶向Na1.5、K1.5和KP通道的新型多靶点药物化合物。
J Biol Chem. 2025 Apr;301(4):108387. doi: 10.1016/j.jbc.2025.108387. Epub 2025 Mar 5.
2
Synthesis, Pharmacological Evaluation, and Molecular Modeling of Lappaconitine-1,5-Benzodiazepine Hybrids.合成、药理学评价及脂乌头碱-1,5-苯并二氮杂卓杂合体的分子模拟。
Molecules. 2023 May 22;28(10):4234. doi: 10.3390/molecules28104234.
3
Inhibitory Effects of Nobiletin on Voltage-Gated Na Channel in Rat Ventricular Myocytes Based on Electrophysiological Analysis and Molecular Docking Method.

本文引用的文献

1
A New Strategy for Multitarget Drug Discovery/Repositioning Through the Identification of Similar 3D Amino Acid Patterns Among Proteins Structures: The Case of Tafluprost and its Effects on Cardiac Ion Channels.通过识别蛋白质结构中相似的三维氨基酸模式进行多靶点药物发现/重新定位的新策略:他氟前列素及其对心脏离子通道影响的案例
Front Pharmacol. 2022 Mar 18;13:855792. doi: 10.3389/fphar.2022.855792. eCollection 2022.
2
A computational method for identifying an optimal combination of existing drugs to repair the action potentials of SQT1 ventricular myocytes.一种计算方法,用于确定现有药物的最佳组合,以修复 SQT1 心室肌细胞的动作电位。
PLoS Comput Biol. 2021 Aug 12;17(8):e1009233. doi: 10.1371/journal.pcbi.1009233. eCollection 2021 Aug.
3
基于电生理分析和分子对接方法研究川陈皮素对大鼠心室肌细胞电压门控钠通道的抑制作用。
Int J Mol Sci. 2022 Dec 2;23(23):15175. doi: 10.3390/ijms232315175.
4
Pyrethroids in an AlphaFold2 Model of the Insect Sodium Channel.昆虫钠通道的AlphaFold2模型中的拟除虫菊酯
Insects. 2022 Aug 18;13(8):745. doi: 10.3390/insects13080745.
PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA.PLIP 2021:将蛋白质-配体相互作用分析器的范围扩展到 DNA 和 RNA。
Nucleic Acids Res. 2021 Jul 2;49(W1):W530-W534. doi: 10.1093/nar/gkab294.
4
Identification of a critical binding site for local anaesthetics in the side pockets of K 1 channels.鉴定 K1 通道侧袋内局部麻醉剂的关键结合位点。
Br J Pharmacol. 2021 Aug;178(15):3034-3048. doi: 10.1111/bph.15480. Epub 2021 May 14.
5
Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms.重新审视用于心房颤动的抗心律失常药物治疗:回顾经验教训并重新定义治疗模式。
Front Pharmacol. 2020 Nov 9;11:581837. doi: 10.3389/fphar.2020.581837. eCollection 2020.
6
Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study.氟卡尼耐受性良好,对房颤患者12个月时有效:一项回顾性研究。
Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720926824. doi: 10.1177/1753944720926824.
7
Use of Flecainide for the Treatment of Atrial Fibrillation.氟卡尼在心房颤动治疗中的应用。
Am J Cardiol. 2020 Apr 1;125(7):1123-1133. doi: 10.1016/j.amjcard.2019.12.041. Epub 2020 Jan 9.
8
Structure of the Cardiac Sodium Channel.心脏钠离子通道的结构。
Cell. 2020 Jan 9;180(1):122-134.e10. doi: 10.1016/j.cell.2019.11.041. Epub 2019 Dec 19.
9
Water Networks Can Determine the Affinity of Ligand Binding to Proteins.水网络可以决定配体与蛋白质的结合亲和力。
J Am Chem Soc. 2019 Oct 9;141(40):15818-15826. doi: 10.1021/jacs.9b06275. Epub 2019 Sep 26.
10
Binding site characterization - similarity, promiscuity, and druggability.结合位点表征——相似性、多配体性和可成药性。
Medchemcomm. 2019 Jun 6;10(7):1145-1159. doi: 10.1039/c9md00102f. eCollection 2019 Jul 1.